Per the latest (2022) American guidelines, guideline-directed medical therapy (GDMT) for HF with reduced ejection fraction (HFrEF) should now comprise four medication categories including sodium-glucose cotransporter-2 inhibitors (SGLT2i) [185]. This evidence concerns the gene SLC5A2 and hydrops fetalis.